Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3965

Sort by

Sort Order Select

Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Blood (2025) 145 (19): 2138–2148.

https://doi.org/10.1182/blood.2024025154

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT

Eduard Schulz, Lauren M. Curtis, Noa G. Holtzman, Jennifer Sponaugle, Kaska Wloka, Alen Ostojic, Alain Mina, Najla El Jurdi, Filip Pirsl, Ashley Carpenter, Mahshid Golagha, Arlene Sirajuddin, Theo Heller, Brian C. Shaffer, Frances T. Hakim, Jeffrey Steven Rubin, Ronald E. Gress, Steven Z. Pavletic

Blood blood.2024028303.

https://doi.org/10.1182/blood.2024028303

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting CD38 with Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia

Zhen Gao, Hong Pan, Lele Zhang, Weiwang Li, Ruonan Li, Jingyu Zhao, Yuechen Luo, Yu Lian, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Yuan Li, Liwei Fang, Meili Ge, Yizhou Zheng, Jun Shi

Blood blood.2025029006.

https://doi.org/10.1182/blood.2025029006

Published: 2025

Includes: Supplemental data

Journal Articles

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Blood blood.2025028357.

https://doi.org/10.1182/blood.2025028357

Published: 2025

Includes: Supplemental data

Journal Articles

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Blood (2025) 145 (18): 2012–2024.

https://doi.org/10.1182/blood.2024026446

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease

Gaurav Goyal, Anne S. Reiner, Dana Bossert, Allison M. Sigler, Mario E. Lacouture, Veronica Rotemberg, Jasmine H. Francis, Ronald S. Go, Raajit K. Rampal, Eli L. Diamond

Blood (2025) 145 (18): 2100–2103.

https://doi.org/10.1182/blood.2024028032

Published: 2025

Includes: Supplemental data

Journal Articles

Counterpoint: The Design and Interpretation of Blood Transfusion Randomized Clinical Trials

Jeffrey L Carson, Paul C Hebert, John H Alexander

Blood blood.2025029042.

https://doi.org/10.1182/blood.2025029042

Published: 2025

Journal Articles

A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma

Blood blood.2024027873.

https://doi.org/10.1182/blood.2024027873

Published: 2025

Includes: Supplemental data

Journal Articles

CAR T cells in autoimmunity: game changer or stepping stone?

Dimitrios Mougiakakos, Everett H. Meyer, Georg Schett

Blood (2025) 145 (17): 1841–1849.

https://doi.org/10.1182/blood.2024025413

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL

Blood (2025) 145 (17): 1890–1902.

https://doi.org/10.1182/blood.2024026381

Published: 2025

Includes: Supplemental data

Journal Articles

Glucarpidase for treatment of high-dose methotrexate toxicity

Shruti Gupta, Sarah A. Kaunfer, Kevin L. Chen, Julie-Alexia Dias, Anitha Vijayan, Arun Rajasekaran, Jason M. Prosek, Huong L. Truong, Anthony Wood, Claude Bassil, Amanda D. Renaghan, Chintan V. Shah, Jingjing Zhang, Ilya Glezerman, Christopher Carlos, Katherine Kelly, Christopher J. Passero, Jan Drappatz, Ala Abudayyeh, Daniel Sanghoon Shin, C. John Sperati, Bradley J. Yelvington, Swetha R. Kanduri, Javier A. Neyra, Daniel Edmonston, Anushree C. Shirali, Anip Bansal, Abdallah Geara, Zain Mithani, Susan L. Ziolkowski, Arash Rashidi, Jonathan Jakubowski, Ashwini Pujari, David A. Bond, Emily Dotson, Sarah Wall, John Patton, Jason N. Barreto, Sandra M. Herrmann, Mohammad S. Sheikh, Rachid Baz, Jamie Lee, Nicholas Lucchesi, Michael Kolman, Muhammad Ahsan Rasheed, Afsheen Afzal, Dasol Kang, Amrita Mahesh, Raymond K. Hsu, Anthony Nicolaysen, Kibrewessen Tefera, Claire Schretlen, Ryan M. Miller, Juan Carlos Velez, Alexander H. Flannery, Abinet M. Aklilu, Shuchi Anand, Soniya Chandrasekhara, Vicki Donley, Ashka Patel, Jian Ni, Shobana Krishnamurthy, Rafia Ali, Osman A. Yilmam, Sophia L. Wells, Jessica L. Ortega, Olivia L. Green-Lingren, Rebecca K. Leaf, Meghan E. Sise, Lakshmi Nayak, Ann S. LaCasce, Nelson Leung, David E. Leaf

Blood (2025) 145 (17): 1858–1869.

https://doi.org/10.1182/blood.2024026211

Published: 2025

Includes: Supplemental data

Journal Articles

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia

Blood (2025) 145 (17): 1943–1956.

https://doi.org/10.1182/blood.2024026886

Published: 2025

Includes: Supplemental data

Journal Articles

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

Blood (2025) 145 (17): 1870–1875.

https://doi.org/10.1182/blood.2024026700

Published: 2025

Includes: Supplemental data

Journal Articles

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Blood (2025) 145 (16): 1780–1787.

https://doi.org/10.1182/blood.2024027342

Published: 2025

Includes: Supplemental data

Journal Articles

HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30 + lymphoma

Ana Carolina Caballero, Cristina Ujaldón-Miró, Paula Pujol-Fernández, Rosanna Montserrat-Torres, Maria Guardiola-Perello, Eva Escudero-López, Irene Garcia-Cadenas, Albert Esquirol, Rodrigo Martino, Paola Jara-Bustamante, Pol Ezquerra, José Manuel Soria, Eva Iranzo, Maria-Estela Moreno-Martinez, Mireia Riba, Jorge Sierra, Carmen Alvarez-Fernández, Laura Escribà-Garcia, Javier Briones

Blood (2025) 145 (16): 1788–1801.

https://doi.org/10.1182/blood.2024026758

Published: 2025

Includes: Supplemental data

Journal Articles

DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis

Sebastiaan Laan, Jessica Del Castillo Alferez, Suzanne Cannegieter, Karin Fijnvandraat, Marieke Kruip, Saskia le Cessie, Ruben Bierings, Jeroen Eikenboom, Iris van Moort

Blood (2025) 145 (16): 1814–1825.

https://doi.org/10.1182/blood.2024026804

Published: 2025

Includes: Supplemental data

Journal Articles

How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions

Andreas Reiter, Georgia Metzgeroth, Nicholas C. P. Cross

Blood (2025) 145 (16): 1758–1768.

https://doi.org/10.1182/blood.2023022417

Published: 2025

Journal Articles

Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL

Colleen Annesley, Kristy D. Seidel, Qian Wu, Corinne Summers, Alan S. Wayne, Michael A. Pulsipher, Anurag K Agrawal, Christopher T Brown, Stephanie Mgebroff, Catherine G Lindgren, Stephanie D. Rawlings-Rhea, Wenjun Huang, Ashley Wilson, Michael C Jensen, Julie R Park, Rebecca A Gardner

Blood blood.2025028359.

https://doi.org/10.1182/blood.2025028359

Published: 2025

Includes: Supplemental data

Journal Articles

ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael B Maris, Paolo Ghia, Michael T. Byrne, Nancy L. Bartlett, John Pagel, Yan Zheng, Justyna Kanska, Wangshu Zhang, Enrique Granados, Javier Pinilla-Ibarz

Blood blood.2024027460.

https://doi.org/10.1182/blood.2024027460

Published: 2025

Includes: Supplemental data

Journal Articles

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Joshua D. Brody, Judit Jørgensen, David Belada, Régis Costello, Marek Trněný, Umberto Vitolo, David John Lewis, Yasmin H. Karimi, Anna Sureda, Marc André, Björn E. Wahlin, Pieternella J. Lugtenburg, Tony Jiang, Kubra Karagoz, Andrew J. Steele, Aqeel Abbas, Liwei Wang, Malene Risum, Raul Cordoba

Blood (2025) 145 (15): 1621–1631.

https://doi.org/10.1182/blood.2024026830

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Phase 1/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT

Targeting CD38 with Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease

Counterpoint: The Design and Interpretation of Blood Transfusion Randomized Clinical Trials

A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma

CAR T cells in autoimmunity: game changer or stepping stone?

Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL

Glucarpidase for treatment of high-dose methotrexate toxicity

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30 + lymphoma

DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis

How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions

Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL

ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only